ContraFect Corp
OTC:CFRXQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ContraFect Corp
OTC:CFRXQ
|
US |
|
G
|
Grandshores Technology Group Ltd
HKEX:1647
|
SG |
|
Sunty Development Co Ltd
TWSE:3266
|
TW |
|
M
|
Minera IRL Ltd
CNSX:MIRL
|
PE |
|
L
|
Lavras Gold Corp
XTSX:LGC
|
CA |
ContraFect Corp
ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. The company is headquartered in Yonkers, New York and currently employs 38 full-time employees. The company went IPO on 2014-07-29. The firm is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa and has demonstrated potent in vivo activity against extensively drug-resistant (XDR) strains. The company has developed an, engineered variant of exebacase, known as CF-296. The company is conducting further in vitro and in vivo characterization of CF-296 to evaluate the full profile of this compound.
ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. The company is headquartered in Yonkers, New York and currently employs 38 full-time employees. The company went IPO on 2014-07-29. The firm is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa and has demonstrated potent in vivo activity against extensively drug-resistant (XDR) strains. The company has developed an, engineered variant of exebacase, known as CF-296. The company is conducting further in vitro and in vivo characterization of CF-296 to evaluate the full profile of this compound.
